Kinnate Biopharma's long-term debt is $2.3M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (December 2023), KNTE shows a long-term debt of $2.3M. That compares with $3.2M in the prior-year period — down 28.5% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, KNTE's long-term debt is now $2.3M (was $3.2M) — a 28.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Kinnate Biopharma is outperforming or lagging.
Tracking KNTE's long-term debt over time shows whether Kinnate Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $2.3M That compares with $3.2M in the prior-year period — down 28.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Kinnate Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $2.3M) with ownership activity and broader fundamentals.
Kinnate Biopharma's long-term debt is $2.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.